Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Assess Safety, Tolerability, and Immunogenicity of V591 (COVID-19 Vaccine) in Healthy Participants (V591-001)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04498247
Recruitment Status : Recruiting
First Posted : August 4, 2020
Last Update Posted : September 14, 2020
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.

Brief Summary:
The primary objective of this early Phase 1 study is to identify the V591 dose that achieves the target immune response in humans based on preclinical or early clinical data.

Condition or disease Intervention/treatment Phase
Coronavirus Disease (COVID-19) Biological: V591 Other: Placebo Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 260 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Phase 1/Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Safety, Tolerability and Immunogenicity of V591 (COVID-19 Vaccine) in Healthy Younger and Older Participants
Actual Study Start Date : August 27, 2020
Estimated Primary Completion Date : April 26, 2022
Estimated Study Completion Date : April 26, 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Part 1: Panels A, B
Participants in this 18 to 55 year old sentinel cohort will receive 2 doses (Day 1 and Day 57) of V591 or placebo.
Biological: V591
1 or 2 ascending doses of V591 will be administered via intramuscular (IM) injection.

Other: Placebo
Placebo (0.9% sodium chloride) administered via IM injection.

Experimental: Part 2A: Panels C-E
Participants in this 18 to 55 year old cohort will receive 1 dose (Day 1) of V591 or placebo.
Biological: V591
1 or 2 ascending doses of V591 will be administered via intramuscular (IM) injection.

Other: Placebo
Placebo (0.9% sodium chloride) administered via IM injection.

Experimental: Part 2A: Panel F
Participants in this 18 to 55 year old cohort will receive 2 doses (Day 1 and Day 169) of V591 or placebo.
Biological: V591
1 or 2 ascending doses of V591 will be administered via intramuscular (IM) injection.

Other: Placebo
Placebo (0.9% sodium chloride) administered via IM injection.

Experimental: Part 2B: Panels G, H
Participants in this ≥60 year old cohort will receive 1 dose (Day 1) of V591 or placebo.
Biological: V591
1 or 2 ascending doses of V591 will be administered via intramuscular (IM) injection.

Other: Placebo
Placebo (0.9% sodium chloride) administered via IM injection.

Experimental: Part 2B: Panels I, J
Participants in this ≥60 year old cohort will receive 2 doses (Day 1 and Day 57) of V591 or placebo.
Biological: V591
1 or 2 ascending doses of V591 will be administered via intramuscular (IM) injection.

Other: Placebo
Placebo (0.9% sodium chloride) administered via IM injection.

Experimental: Part 2B: Panels K, L
Participants in this ≥60 year old cohort will receive 2 doses (Day 1 and Day 169) of V591 or placebo.
Biological: V591
1 or 2 ascending doses of V591 will be administered via intramuscular (IM) injection.

Other: Placebo
Placebo (0.9% sodium chloride) administered via IM injection.




Primary Outcome Measures :
  1. Percentage of Participants with at Least 1 Solicited Injection Site Adverse Event [ Time Frame: Up to ~5 days after vaccination ]
    An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

  2. Percentage of Participants with at Least 1 Solicited Systemic Adverse Event [ Time Frame: Up to ~14 days after vaccination ]
    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

  3. Percentage of Participants with at Least 1 Unsolicited Adverse Event [ Time Frame: Up to ~28 days after vaccination ]
    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

  4. Percentage of Participants with at Least 1 Serious Adverse Event [ Time Frame: Up to ~365 days (±14 days) after vaccination ]
    A serious adverse event is "life threatening," requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity and is a congenital anomaly/birth defect.

  5. Percentage of Participants who Discontinued Study Treatment due to an Adverse Event [ Time Frame: Up to ~365 days (±7 days) after vaccination ]
    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

  6. Percentage of Participants with at Least 1 Medically Attended Adverse Event [ Time Frame: Up to ~365 days (±14 days) after vaccination ]
    A medically attended adverse event (MAAE) is an AE in which medical attention is received during an unscheduled, non-routine outpatient visit, such as an emergency room visit, office visit, or an urgent care visit with any medical personnel for any reason.


Secondary Outcome Measures :
  1. Geometric Mean Titers for Serum Neutralizing Antibodies (nAb) as Measured by Plaque Reduction Neutralization Test (PRNT): All Panels [ Time Frame: Day 29 ]
    Serum samples will be collected and the presence of serum neutralization antibodies will be assessed using PRNT.

  2. Geometric Mean Concentration of Total Anti-Spike Immunoglobulin G (IgG) Antibodies as Measured by Enzyme-Linked Immunosorbent Assay (ELISA): All Panels [ Time Frame: Day 29 ]
    Serum samples will be collected and the total anti-spike IgG antibodies will be assessed using ELISA.

  3. Geometric Mean Titers for Serum Neutralizing Antibodies as Measured by PRNT: Panels A,B, I and J [ Time Frame: Day 85 ]
    Serum samples will be collected and the presence of serum neutralization antibodies will be assessed using PRNT.

  4. Geometric Mean Concentration of Total Anti-Spike IgG Antibodies as Measured by ELISA: Panels A,B, I and J [ Time Frame: Day 85 ]
    Serum samples will be collected and the total anti-spike IgG antibodies will be assessed using ELISA.

  5. Geometric Mean Titers for Serum Neutralizing Antibodies as Measured by PRNT: Panels K and L [ Time Frame: Day 197 ]
    Serum samples will be collected and the presence of serum neutralization antibodies will be assessed using PRNT.

  6. Geometric Mean Concentration of Total Anti-Spike IgG Antibodies as Measured by ELISA: Panels K and L [ Time Frame: Day 197 ]
    Serum samples will be collected and the total anti-spike IgG antibodies will be assessed using ELISA.

  7. Geometric Mean Titers for Serum nAb as Measured by PRNT [ Time Frame: Panels C-E and G-H: Days 1, 15, 29, 57, 85, 115, 211, and 365; Panels A,B, I and J: Days 1, 15, 29, 57, 71, 85, 115, 211, and 422; Panels F, K and L: Days 1, 15, 29, 85, 169, 197, 365 and 534 ]
    Serum samples will be collected and the presence of serum neutralization antibodies will be assessed using PRNT.

  8. Geometric Mean Concentration of Total Anti-Spike IgG Antibodies as Measured by ELISA [ Time Frame: Panels C-E and G-H: Days 1, 15, 29, 57, 85, 115, 211, and 365; Panels A,B, I and J: Days 1, 15, 29, 57, 71, 85, 115, 211, and 422; Panels F, K and L: Days 1, 15, 29, 85, 169, 197, 365 and 534 ]
    Serum samples will be collected and the total anti-spike IgG antibodies will be assessed using ELISA.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Is in overall good health based on medical history, physical examination, electrocardiogram (ECG) and vital sign (VS) measurements performed prior to randomization.
  • Is in overall good health based on laboratory safety tests obtained at the screening visit.
  • Has a body mass index (BMI) ≤30 kg/m2 inclusive (after rounding to the nearest whole number).
  • Has been practicing social distancing for at least two weeks prior to planned Day 1 vaccination and has no close contacts with known active severe acute respiratory syndrome coronavirus (SARS-CoV)-2 infection in that time period.
  • Is male or female, from 18 years to 55 years of age (inclusive) (Parts 1 and 2A) or ≥60 years of age (Part 2B), at the time of signing the informed consent.
  • Male participants are eligible to participate if they agree to refrain from donating sperm, be abstinent from heterosexual intercourse as their preferred and usual lifestyle and agree to remain abstinent or agree to use contraception during the intervention period and for at least 6 months after the last dose of study intervention.
  • Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
  • A female participant is eligible to participate if she is not pregnant or breastfeeding, is not a woman of childbearing potential (WOCBP) or Is a WOCBP and using an acceptable contraceptive method or be abstinent from heterosexual intercourse as their preferred and usual lifestyle.
  • A WOCBP must have a negative highly sensitive pregnancy test (urine or serum as required by local regulations) before the first dose of study intervention. If a urine test cannot be confirmed as negative (e.g., an ambiguous result), a serum pregnancy test is required. In such cases, the participant must be excluded from participation if the serum pregnancy result is positive.
  • Refrain from donating oocyte during the intervention period and for at least 6 months after the last dose of study intervention.
  • The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy.
  • The participant provides written informed consent/assent for the study, including for future biomedical research.
  • Is willing to comply with the study restrictions, including social distancing between screening and randomization.
  • Is willing to abstain from donating whole blood or blood derivatives, tissue or organ all along the study.
  • Agrees to provide study personnel with a primary telephone number as well as an alternate means of contact, if available (such as an alternate telephone number or email) for follow-up purposes.
  • Can read, understand, and complete the Vaccination Report Card.

Exclusion Criteria

  • Is currently actively infected with SARS-CoV-2 (confirmed by polymerase chain reaction;[PCR]).
  • Has prior medical history of confirmed SARS-CoV-2 infection or known exposure to an individual with confirmed coronavirus disease 2019 (COVID-19) disease or SARS-CoV-2 infection within the past 2 weeks. Participants will not be screened for enrollment by SARS-CoV-2 serology, allowing those who may have had a prior asymptomatic SARS-CoV-2 infection to be enrolled.
  • Has a history of severe adverse reactions to vaccine administration, including anaphylaxis and related symptoms, such as urticaria, respiratory difficulty, angioedema and abdominal pain to vaccines, or history of known or suspected allergic reaction likely to be exacerbated by any component of the COVID-19 vaccine.
  • Is currently (or highly suspected to be) immunocompromised, including anticipating the need for systemic immunosuppressive treatment within the next 6 months or 12 months for 2-dose Day 1, Day 169 panels or has been diagnosed or highly suspected as having a congenital or acquired immunodeficiency, HIV infection, lymphoma, leukemia, systemic lupus erythematosus (SLE), rheumatoid arthritis, juvenile rheumatoid arthritis (JRA), inflammatory bowel disease, or other autoimmune condition that could impact the immune response or the safety of the study vaccine.
  • Has clinically significant thrombocytopenia or other coagulation disorder contraindicating intramuscular vaccination or repeated venipuncture.
  • Has history or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study or interfere with the participant's participation for the full duration of the study.
  • Has a history or presence of clinically significant pulmonary disorders (e.g. chronic obstructive pulmonary disease [COPD], etc.), or asthma.
  • Has a history of confirmed SARS-CoV-1 or Middle Eastern respiratory syndrome (MERS)
  • Has a history of or current clinically significant medical condition that puts the participant at increased risk for severe SARS-CoV-2 disease, such as cancer, chronic kidney disease, COPD, immunocompromised state (weakened immune system) from solid organ transplant, obesity (BMI of 30 or higher), serious heart conditions, such as heart failure, coronary artery disease, or cardiomyopathies, sickle cell disease, or Type 2 diabetes mellitus.
  • Is mentally or legally incapacitated, has significant emotional problems at the time of pre-study (screening) visit or expected during the conduct of the study or has a history of clinically significant psychiatric disorder of the last 5 years.
  • Has a history of any clinically significant major neurological disorders or seizures (including Guillain-Barré syndrome), with the exception of febrile seizures during childhood.
  • Has a history of cancer (malignancy)
  • Has a known or suspected history of significant multiple and/or severe allergies (e.g., food, drug, latex allergy), or has had an anaphylactic reaction or significant intolerability (i.e., systemic allergic reaction) to prescription or non-prescription drugs or food.
  • Is positive for hepatitis B surface antigen (HBsAg), hepatitis C antibodies or human immunodeficiency virus (HIV)-1 or 2 antibodies. Individuals with antibodies to hepatitis C may be enrolled if hepatitis C viral load is undetectable and there is no evidence of or history of liver disease.
  • Had major surgery, donated or lost 1 unit of blood (approximately 500 mL) within 4 weeks prior to the pre-study (screening) visit.
  • Has received immunosuppressive drugs (like e.g. systemic corticosteroids, excluding topical preparations and inhalers) within 3 months prior to the first vaccination or 6 months for chemotherapies.
  • Has received a blood transfusion or blood products, including immunoglobulin, starting from 3 months before the first study vaccination or is scheduled to receive a blood transfusion or blood product through study completion. Autologous blood transfusions are not considered an exclusion criterion.
  • Is unable to meet the concomitant medication restrictions
  • Is using antiviral medications or any investigational agents for prophylaxis of SARSCoV-2 within 4 weeks prior to the first vaccination.
  • Has ever participated in an investigational study of a SARS-CoV-2 vaccine, or an antiviral or other biologic product intended for the treatment of COVID-19.
  • Has participated in another vaccine study within 3 months prior to screening or has participated in an investigational study within 4 weeks prior to the pre-study (screening) visit.
  • Has glycated hemoglobin (A1C) ≥ 6.5% at screening.
  • Has a history of alcohol, cocaine, or opioid abuse during the previous 3 years.
  • Participants who currently smoke or used nicotine or nicotine-containing products (e.g. nicotine patch) within last 3 months. Former smokers that have less than a 10 pack-year history of smoking and have not smoked in the last 12 months are eligible to be enrolled.
  • Has a tattoo, scar or other physical finding at the area of the vaccination site that would interfere with intramuscular injection or a local tolerability assessment.
  • Presents any concern by the investigator regarding safe participation in the study or for any other reason the investigator considers the participant inappropriate for participation in the study.
  • Lives in a nursing home or long-term care facility.
  • Is currently working in occupations with high risk of exposure to SARS-CoV-2 (e.g., health care worker with direct patient contact, emergency response personnel), or, at the investigator's discretion to be at increased risk to acquire SARS-CoV-2 for any other reason.
  • Individuals who are living and/or working with severely immunocompromised people, pregnant women, lactating women, children under 12 months old, or any other individual that, in the judgment of the investigator, might be at increased risk.
  • Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigatively involved with this study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04498247


Contacts
Layout table for location contacts
Contact: Toll Free Number 1-888-577-8839 Trialsites@merck.com

Locations
Layout table for location information
Belgium
Universitair Ziekenhuis Gent ( Site 0003) Recruiting
Gent, Oost-Vlaanderen, Belgium, 9000
Contact: Study Coordinator    +3293320050      
SGS Life Science Services ( Site 0001) Recruiting
Antwerpen, Belgium, 2060
Contact: Study Coordinator    +3232172560      
ATC - Clinical Pharmacology Unit ( Site 0002) Recruiting
Liege, Belgium, 4000
Contact: Study Coordinator    +3243668306      
Sponsors and Collaborators
Merck Sharp & Dohme Corp.
Investigators
Layout table for investigator information
Study Director: Medical Director Merck Sharp & Dohme Corp.
Layout table for additonal information
Responsible Party: Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier: NCT04498247    
Other Study ID Numbers: V591-001
2020-003493-46 ( EudraCT Number )
V591-001 ( Other Identifier: Merck )
First Posted: August 4, 2020    Key Record Dates
Last Update Posted: September 14, 2020
Last Verified: September 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
URL: http://engagezone.msd.com/ds_documentation.php

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Virus Diseases